China trial shows Gilead's drug does not show benefits in COVID-19 patients - Lancet - (Yahoo!Finance via NewsPoints Desk)

  • According to data published in The Lancet, Gilead Sciences' remdesivir did not speed up recovery from COVID-19 versus placebo in critically-ill, hospitalised patients enrolled in a Chinese trial, as reported in Yahoo!Finance.

  • The authors warned that interpreting the finding is limited as the study was stopped early after they were unable to recruit enough patients due to the steep decline in cases in China.

  • They added that more evidence from ongoing trials is needed to better understand if remdesivir can provide meaningful clinical benefit.

To read more NewsPoints articles, click here.